Boehringer Ingelheim and Sino Biopharmaceutical today announced a strategic multi-program option and license agreement to develop next-generation cancer therapies. Sino Biopharm will receive USD358 million upfront, with potential milestone payments of up to USD7 billion, plus tiered royalties.